GlassScriptPhysician profile
Le A Tran
NPI 1689122525
$7,821.57
in general payments reported to CMS, 2019-2025
30 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,914 · 2022: $1,448 · 2023: $1,556 · 2024: $1,476 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,459.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $992.09 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Travere Therapeutics, INC. | $951.88 | 2022-2025 | Filspari |
| Amgen INC. | $713.97 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $619.91 | 2021-2024 | Farxiga |
| Vifor Pharma, INC. | $543.33 | 2021-2023 | Veltassa, Korsuva |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $374.86 | 2021-2025 | Jynarque |
| Glaxosmithkline, LLC. | $370.72 | 2021-2025 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $348.96 | 2021-2023 | |
| Aurinia Pharma U.S., INC. | $318.31 | 2021-2024 | Lupkynis |
| Ardelyx, INC. | $292.07 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Calliditas Therapeutics US INC. | $272.78 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $247.15 | 2021-2023 | Injectafer |
| Novo Nordisk INC | $222.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Opko Pharmaceuticals, LLC | $202.32 | 2021-2024 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $179.33 | 2021-2025 | Ultomiris |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $177.12 | 2022-2023 | Krystexxa |
| Akebia Therapeutics INC | $170.94 | 2021-2025 | Vafseo |
| Recor Medical INC | $159.31 | 2024 | Paradise Renal Denervation System |
| Otsuka America Pharmaceutical, INC. | $157.50 | 2021-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $106.67 | 2021-2025 | Terlivaz |
| Shield Therapeutics INC | $88.85 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $46.28 | 2021-2023 | |
| Pharmacosmos Therapeutics INC. | $42.66 | 2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $41.97 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $41.57 | 2022 | |
| Ani Pharmaceuticals, INC. | $40.58 | 2022 | |
| Lilly USA, LLC | $38.79 | 2023-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.99 | 2023 | Jardiance |
| Chiesi USA, INC. | $15.27 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Le Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.